Lupin Secures U.S. FDA Approval for Phytonadione Injectable Emulsion Prefilled Syringe
Lupin Ltd 路 Press Release 路 09 Oct 2026, 2:28 am
Lupin Secures U.S. FDA Approval for Phytonadione Injectable Emulsion Prefilled Syringe Lupin Limited received U.S. FDA approval on 8th Oct'26 for its ANDA covering Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL single-dose prefilled syringe. The generic is bioequivalent to International Medication Systems' reference listed drug and is indicated for the treatment and prophylaxis of hypoprothrombinemia and vitamin K-deficiency. According to IQVIA MAT Aug'26 data, Phytonadione Injectable Emulsion generated estimated annual sales of USD 52.3 million in the U.S. market, expanding Lupin鈥檚 injectable portfolio.
Original exchange filing (PDF)
More announcements from Lupin Ltd
- Lupin Announces European Launch of Biosimilar Ranibizumab. 路 12 Nov 2026
- Transcript of Q2 FY2027 Earnings Conference Call. 路 07 Nov 2026
- Link of Audio recording of the Earnings Call-Q2 FY27. 路 05 Nov 2026
- Investor Presentation- Q2 FY2027 路 04 Nov 2026
- Lupin Q2 FY2027 Results 路 04 Nov 2026
- Appointment of Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026 and as an Independent Director for a term of five consecutive years with .... 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. 路 04 Nov 2026
